{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:14:25Z","timestamp":1776323665447,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Long-acting triptorelin (LAT) (22.5 mg) is a gonadotropin-releasing hormone (GnRH) agonist used in men with prostate cancer. This study investigated the prescription pattern of LAT in a real-world setting and its efficacy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients &amp; methods<\/jats:title>\n            <jats:p>This was a retrospective review of patients in a tertiary center who were prescribed LAT for prostate cancer from January 2018 to March 2023 after the introduction of LAT in the territory. Demographic data were collected, and LAT prescription patterns were reviewed. These patterns included the indication and duration of prescription, testosterone suppression and characteristics of the primary prostate cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 237 prostate cancer patients were prescribed LAT in the study period. The indications for LAT included metastatic prostate cancer (50.6%), neoadjuvant\/adjuvant therapy for radiotherapy (28.7%) and neoadjuvant therapy for radical prostatectomy (5.1%). Among the cohort, 41.4% of the patients were receiving short-acting triptorelin (11.25 mg) before LAT initiation, 15.2% were receiving other GnRH agonists, and 15.6% were receiving GnRH antagonists. The median age at the first dose of LAT and the median treatment duration were 72 (53\u201394) years and 30 (6\u201372) months, respectively. During the study period, 92.0% of the patients did not receive another form of hormonal treatment other than LAT. A total of 121 (51.1%) patients had their testosterone level checked after LAT initiation. The median time interval of testosterone measurement after LAT initiation was 8 (1\u201347) months, with 98.3% of the patients having a testosterone level\u2009&lt;\u20091.7 nmol\/L and 92.6% having a level\u2009&lt;\u20090.7 nmol\/L. Among the cohort, 1 patient stopped LAT due to hot flashes and muscle weakness.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The LAT adherence rate was high in the setting of hormonal treatment for prostate cancer. Testosterone suppression was satisfactory after the initiation of LAT and was generally well tolerated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12894-025-01717-7","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T11:01:12Z","timestamp":1740481272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A 6-month sustained-release formulation of triptorelin for locally advanced or metastatic prostate cancer: a real-world experience in Asia"],"prefix":"10.1186","volume":"25","author":[{"given":"Chi-Hang","family":"Yee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuen-Hei","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan Ching-Ho","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris Ho-Ming","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Mok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Ka-Fung","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Fai","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"1","key":"1717_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38\u201352.","journal-title":"Eur Urol"},{"issue":"4","key":"1717_CR2","first-page":"710","volume":"14","author":"F Fathollahi","year":"2023","unstructured":"Fathollahi F, Khazaei Z, Abbasi M, Goodarzi E. Burden of prostate cancer and relationship with the human development index (HDI) in Asia: A study of Global Burden disease in 2019. Caspian J Intern Med. 2023;14(4):710\u20139.","journal-title":"Caspian J Intern Med"},{"issue":"1","key":"1717_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, de Pereira Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13\u201324.","journal-title":"N Engl J Med."},{"issue":"5","key":"1717_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686\u2013700.","journal-title":"Lancet Oncol"},{"issue":"32","key":"1717_CR5","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974\u201386.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1717_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333.","journal-title":"N Engl J Med"},{"issue":"2","key":"1717_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152\u201360.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1717_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11912-024-01509-6","volume":"26","author":"G Grisay","year":"2024","unstructured":"Grisay G, Lavaud P, Fizazi K. Current systemic therapy in men with metastatic castration-sensitive prostate cancer. Curr Oncol Rep. 2024;26(5):488\u201395.","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"1717_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.31128\/AJGP-11-23-7028","volume":"53","author":"D Homewood","year":"2024","unstructured":"Homewood D, Fu MH, Sathianathen N, La Bianca S, Tran B, Corcoran NM. Evolution of hormonal therapy for prostate cancer. Aust J Gen Pract. 2024;53(5):291\u2013300.","journal-title":"Aust J Gen Pract"},{"issue":"23","key":"1717_CR10","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.3390\/cancers15235615","volume":"15","author":"S Wasim","year":"2023","unstructured":"Wasim S, Park J, Nam S, Kim J. Review of current treatment intensification strategies for prostate cancer patients. Cancers (Basel). 2023;15(23):5615.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"1717_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/20514158211022216","volume":"16","author":"SS Bennett","year":"2023","unstructured":"Bennett SS, Leung HY, Ahmad I. A cohort analysis of patients receiving neoadjuvant androgen deprivation therapy prior to robot-assisted laparoscopic prostatectomy during the Covid-19 pandemic. J Clin Urol. 2023;16(2):131\u20139.","journal-title":"J Clin Urol"},{"issue":"33","key":"1717_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40267-017-0413-y","volume":"2017","author":"KAL-W Kate McKeage","year":"2017","unstructured":"Kate McKeage KAL-W. Triptorelin 3- and 6-month sustained-release formulations in locally advanced or metastatic prostate cancer. a profile of their use in the EU. Drugs Ther Perspect. 2017;2017(33):321\u20135.","journal-title":"Drugs Ther Perspect"},{"issue":"7","key":"1717_CR13","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1007\/s12325-016-0351-4","volume":"33","author":"AS Merseburger","year":"2016","unstructured":"Merseburger AS, Hupe MC. An update on triptorelin: current thinking on androgen deprivation therapy for prostate cancer. Adv Ther. 2016;33(7):1072\u201393.","journal-title":"Adv Ther"},{"issue":"12","key":"1717_CR14","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402\u201318.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1717_CR15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s12094-018-1940-2","volume":"21","author":"A Gomez-Caamano","year":"2019","unstructured":"Gomez-Caamano A, Gonzalez-San Segundo C, Henriquez I, Maldonado X, Zapatero A, Expert Panel for the Consensus on Management of Castration-Resistant Prostate Cancer UTWGSSoRO. Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology. Clin Transl Oncol. 2019;21(4):420\u201332.","journal-title":"Clin Transl Oncol."},{"issue":"41","key":"1717_CR16","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.3346\/jkms.2021.36.e256","volume":"36","author":"JH Ryu","year":"2021","unstructured":"Ryu JH, Kim YB, Jung TY, Ko WJ, Kim SI, Kwon D, et al. Practice patterns of Korean urologists regarding positive surgical margins after radical prostatectomy: a survey and narrative review. J Korean Med Sci. 2021;36(41):e256.","journal-title":"J Korean Med Sci"},{"issue":"1","key":"1717_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1245\/s10434-018-7035-z","volume":"26","author":"TR McClintock","year":"2019","unstructured":"McClintock TR, von Landenberg N, Cole AP, Lipsitz SR, Gild P, Sun M, et al. Neoadjuvant androgen deprivation therapy prior to radical prostatectomy: recent trends in utilization and association with postoperative surgical margin status. Ann Surg Oncol. 2019;26(1):297\u2013305.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"1717_CR18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0090-4295(00)00793-7","volume":"56","author":"MG Oefelein","year":"2000","unstructured":"Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56(6):1021\u20134.","journal-title":"Urology"},{"issue":"1\u20132","key":"1717_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5489\/cuaj.4303","volume":"11","author":"L Klotz","year":"2017","unstructured":"Klotz L, Breau RH, Collins LL, Gleave ME, Pickles T, Pouliot F, et al. Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Can Urol Assoc J. 2017;11(1\u20132):16\u201323.","journal-title":"Can Urol Assoc J"},{"issue":"5","key":"1717_CR20","first-page":"252","volume":"62","author":"P Teillac","year":"2004","unstructured":"Teillac P, Heyns CF, Kaisary AV, Bouchot O, Blumberg J. Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer. Horm Res. 2004;62(5):252\u20138.","journal-title":"Horm Res"},{"issue":"12","key":"1717_CR21","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2165\/11319690-000000000-00000","volume":"29","author":"EA Lundstrom","year":"2009","unstructured":"Lundstrom EA, Rencken RK, van Wyk JH, Coetzee LJ, Bahlmann JC, Reif S, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig. 2009;29(12):757\u201365.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1717_CR22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s12325-016-0466-7","volume":"34","author":"J Breul","year":"2017","unstructured":"Breul J, Lundstrom E, Purcea D, Venetz WP, Cabri P, Dutailly P, et al. Efficacy of testosterone suppression with sustained-release triptorelin in advanced prostate cancer. Adv Ther. 2017;34(2):513\u201323.","journal-title":"Adv Ther"},{"issue":"2","key":"1717_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1756287217738985","volume":"10","author":"D Meani","year":"2018","unstructured":"Meani D, Solaric M, Visapaa H, Rosen RM, Janknegt R, Soce M. Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care. Ther Adv Urol. 2018;10(2):51\u201363.","journal-title":"Ther Adv Urol"},{"issue":"6","key":"1717_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/1756287214542418","volume":"6","author":"T Lebret","year":"2014","unstructured":"Lebret T, Davin JL, Hennequin C, Latorzeff I, Mignard JP, Moreau JL, et al. Selection criteria for initiation and renewal of luteinizing hormone-releasing hormone agonist therapy in patients with prostate cancer: a French prospective observational study. Ther Adv Urol. 2014;6(6):205\u201314.","journal-title":"Ther Adv Urol"},{"issue":"2","key":"1717_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.5534\/wjmh.230042","volume":"42","author":"J Lim","year":"2024","unstructured":"Lim J, Ng CF, Wei Y, Ong TA, Chu PS, Chan WKW, et al. Health-related quality of life assessment in prostate cancer patient undergoing androgen deprivation therapy: real-world experience in the READT Study. World J Mens Health. 2024;42(2):449\u201359.","journal-title":"World J Mens Health"},{"issue":"5","key":"1717_CR26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jaccao.2023.05.011","volume":"5","author":"AJ Nelson","year":"2023","unstructured":"Nelson AJ, Lopes RD, Hong H, Hua K, Slovin S, Tan S, et al. Cardiovascular effects of GnRH antagonists compared with agonists in prostate cancer: a systematic review. JACC CardioOncol. 2023;5(5):613\u201324.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"1717_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/JU.0000000000003721","volume":"211","author":"ED Crawford","year":"2024","unstructured":"Crawford ED, Hafron JM, Debruyne F, Wallis C, Chang S, Garnick MB. Cardiovascular risk in prostate cancer patients using luteinizing hormone-releasing hormone agonists or a gonadotropin-releasing hormone antagonist. J Urol. 2024;211(1):63\u201370.","journal-title":"J Urol"},{"issue":"3","key":"1717_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/JU.0000000000003830","volume":"211","author":"J Stira","year":"2024","unstructured":"Stira J, Gravina C, Lombardo R, De Nunzio C. Letter: cardiovascular risk in prostate cancer patients using luteinizing hormone-releasing hormone agonists or a gonadotropin-releasing hormone antagonist. J Urol. 2024;211(3):481.","journal-title":"J Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01717-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01717-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01717-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T11:01:15Z","timestamp":1740481275000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01717-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1717"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01717-7","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was not needed for this study because it was retrospective in nature. All protocols received approval from the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee (CREC Ref. No. 2023.180). The clinical trial was registered at ClinicalTrials.gov (ID: NCT06217770).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable (not required by the IRB).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}